
Guidance for Industry

Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Janet Norden at 301-796-2270, or (CBER) Toni Stifano at 301-827-6190.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**January 2006
Labeling**

Guidance for Industry

Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format

Additional copies are available from:

*Office of Training and Communications
Division of Drug Information, HFD-210
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573*

(Internet) <http://www.fda.gov/cder/guidance/index.htm>

or

*Office of Communication, Training and
Manufacturers Assistance, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Rockville, MD 20852-1448
(Tel) 800-835-4709 or 301-827-1800
(Internet) <http://www.fda.gov/cber/guidelines.htm>.*

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**January 2006
Labeling**

Contains Nonbinding Recommendations

Draft — Not for Implementation

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	WARNINGS AND PRECAUTIONS SECTION (§ 201.57(c)(6)).....	2
A.	Adverse Reactions and Information to Include	2
1.	<i>Observed Adverse Reactions.....</i>	<i>2</i>
2.	<i>Expected Adverse Reactions</i>	<i>2</i>
3.	<i>Additional Considerations</i>	<i>3</i>
4.	<i>Adverse Reactions Associated with Unapproved Uses</i>	<i>4</i>
5.	<i>Drug Interactions.....</i>	<i>4</i>
6.	<i>Monitoring</i>	<i>4</i>
B.	Information to Provide	4
C.	Format.....	5
1.	<i>Subheadings.....</i>	<i>5</i>
2.	<i>Order of Adverse Reactions</i>	<i>6</i>
3.	<i>Emphasis in Text.....</i>	<i>6</i>
4.	<i>Cross-Referencing.....</i>	<i>6</i>
III.	CONTRAINDICATIONS SECTION (§ 201.57(c)(5))	6
A.	When to Contraindicate	6
1.	<i>Observed Adverse Reactions.....</i>	<i>6</i>
2.	<i>Expected Adverse Reactions</i>	<i>7</i>
3.	<i>Likely Clinical Situations.....</i>	<i>7</i>
B.	Information to Provide	8
C.	Format.....	8
1.	<i>Subheadings.....</i>	<i>8</i>
2.	<i>Order of Contraindications.....</i>	<i>8</i>
3.	<i>Text Emphasis.....</i>	<i>9</i>
IV.	BOXED WARNING (§ 201.57(c)(1))	9
A.	When to Use a Boxed Warning.....	9
B.	Information to Provide	10
C.	Format.....	10
	GLOSSARY.....	11

1
2
3
4
5
6
7
8
9

Guidance for Industry¹

Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format²

10
11
12
13
14
15
16
17

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

18
19
20

I. INTRODUCTION

21
22
23
24
25
26
27
28
29

This guidance is intended to assist applicants and reviewers in drafting the WARNINGS AND PRECAUTIONS, CONTRAINDICATIONS, and BOXED WARNING sections of labeling, as described in the final rule amending the requirements for the content and format of labeling for human prescription drug and biological products (21 CFR 201.56 and 201.57).³ The recommendations in this guidance are intended to help ensure that the labeling is clear, useful, informative, and to the extent possible, consistent in content and format.

30
31

This guidance provides recommendations on the following:

32
33
34

- How to decide which adverse reactions are significant enough to warrant inclusion in the WARNINGS AND PRECAUTIONS section; what information to include when describing those adverse reactions; and how to organize the section

¹ This guidance has been prepared by the Medical Policy Coordinating Committees in the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.

² This guidance applies to drugs, including biological drug products. For the purposes of this guidance, *drug product* or *drug* will be used to refer to human prescription drug and biological products that are regulated as drugs.

³ See the final rule “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products” published in the *Federal Register* in January 2006.

Contains Nonbinding Recommendations

Draft — Not for Implementation

- 35 • What situations warrant a contraindication; what information to provide in those
36 situations when the use of the product is contraindicated; and how to organize the
37 CONTRAINDICATIONS section
- 38 • When to include a boxed warning; and what information to include in the BOXED
39 WARNING section

40
41 FDA's guidance documents, including this guidance, do not establish legally enforceable
42 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should
43 be viewed only as recommendations, unless specific regulatory or statutory requirements are
44 cited. The use of the word *should* in Agency guidances means that something is suggested or
45 recommended, but not required.

46

II. WARNINGS AND PRECAUTIONS SECTION (§ 201.57(c)(6))

47

A. Adverse Reactions and Information to Include

48

1. Observed Adverse Reactions

49

50
51 This section includes clinically significant adverse reactions observed in association with
52 the use of a drug for which there is reasonable evidence of a causal association between
53 the drug and the adverse reaction (a causal relationship need not have been established):

54

IF

55

- 56 • The adverse reaction is serious (see glossary for definition of serious adverse
57 reaction).

58

OR

59

- 60 • The adverse reaction does not meet the definition of a serious adverse reaction, but is
61 still considered clinically significant (*otherwise clinically significant*). Adverse
62 reactions that are considered *otherwise clinically significant* could include:

63

64 — Adverse reactions that require discontinuation, dosage or regimen adjustment,
65 or addition of another drug

66

67 — Adverse reactions that could be prevented or managed with appropriate patient
68 selection or avoidance of concomitant therapy

69

68 — Adverse reactions that significantly affect patient compliance

69

OR

70

- 70 • The product interferes with a laboratory test.

71

2. Expected Adverse Reactions

72

73 There are circumstances in which an adverse reaction can be expected to occur with a
74 drug, despite its not having been observed with that drug, based on observations from

Contains Nonbinding Recommendations

Draft — Not for Implementation

75 other members of the drug class or animal studies. An expected adverse reaction may not
76 be observed, for example, in clinical trials for newer drugs in a class where the trials are
77 designed to exclude populations that were determined to be vulnerable to the adverse
78 reaction with earlier members of the drug class.

79
80 The WARNINGS AND PRECAUTIONS section includes adverse reactions that are
81 expected to occur with a drug, but have yet to be observed if:

- 82
83 • The reaction is *serious* or *otherwise clinically significant* as discussed above

84
85 ***AND EITHER***

- 86 • Based on what is known about the pharmacology, chemistry, or class of the drug, it
87 appears likely that the adverse reaction will occur with the drug.

88 ***OR***

- 89 • Animal data raise substantial concern about the potential for occurrence of the
90 adverse reaction in humans (e.g., animal data demonstrating that a drug has
91 teratogenic effects).

92 In these cases, the labeling should acknowledge that the adverse reaction has not been
93 observed, but may be expected to occur.

94
95 ***3. Additional Considerations***

96
97 The following factors should also be considered in determining whether to include an
98 adverse reaction in the WARNINGS AND PRECAUTIONS section of labeling:

- 99
100 • Indication

101
102 The relative seriousness of the disease or condition for which a drug is indicated will
103 influence whether an adverse reaction would be considered clinically significant and thus
104 appropriate for inclusion in the WARNINGS AND PRECAUTIONS section. For
105 example, for a drug intended to treat a minor, self-limiting condition (e.g., allergic
106 rhinitis, cosmetic conditions, transient insomnia), a nonserious adverse reaction (e.g.,
107 nausea, pruritis, alopecia) may be considered clinically significant and, therefore,
108 appropriate for inclusion in the section. For a drug intended to treat a serious or life-
109 threatening condition (e.g., cancer), the same adverse reaction may be considered much
110 less clinically significant and not appropriate for inclusion in the section.

Contains Nonbinding Recommendations

Draft — Not for Implementation

111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156

- Incidence

Typically, the nature of an adverse reaction and a drug's indication are the most influential factors in determining whether an adverse reaction should be included in the WARNINGS AND PRECAUTIONS section. In some cases, however, the absolute risk or rate of an adverse reaction can be an important factor when deciding whether to include the reaction in this section (e.g., when the risk or rate is high).

- Ability to Manage or Prevent an Adverse Reaction

The ability to manage or prevent an adverse reaction through patient monitoring, proper dose selection or titration, or avoidance of concomitant therapy can also be an important factor in deciding whether to discuss an adverse reaction in the WARNINGS AND PRECAUTIONS section.

4. Adverse Reactions Associated with Unapproved Uses

FDA may require a specific warning relating to an unapproved use if the drug is commonly prescribed for a disease or condition and such usage is associated with a clinically significant risk or hazard (§ 201.57(c)(6)(i)). Clinically significant adverse reactions that appear to be linked primarily to an unapproved use of a drug (e.g., use for a disease, condition, or population not included in the INDICATIONS AND USE section, use of an unapproved dose or regimen) should be identified and discussed in the WARNINGS AND PRECAUTIONS section. The discussion should include a statement indicating that safety and effectiveness have not been established in that setting and that the use is not approved by FDA.

5. Drug Interactions

The WARNINGS AND PRECAUTIONS section should include a discussion of any known or predicted drug interactions with serious or otherwise clinically significant outcomes, with a cross-reference to any additional information in the DRUG INTERACTIONS or CLINICAL PHARMACOLOGY sections.

6. Monitoring

The WARNINGS AND PRECAUTIONS section must identify any laboratory tests helpful in following the patient's response or in identifying possible adverse reactions (§ 201.57(c)(6)(iii)), and, if appropriate, information about the frequency of testing and expected ranges of normal and abnormal values.

B. Information to Provide

The WARNINGS AND PRECAUTIONS section should contain the following information for each adverse reaction, if such information is known:

Contains Nonbinding Recommendations

Draft — Not for Implementation

- 157
158
159
- A description of the adverse reaction and outcome (e.g., time to resolution, significant sequelae)
 - 160 • An estimate of risk or adverse reaction rate⁴
 - 161 • A discussion of known risk factors for the adverse reaction (e.g., age, gender, race,
162 comorbid conditions, dose, duration of use, coadministered drugs)
 - 163 • A discussion of steps to take to reduce the risk of, decrease the likelihood of, shorten
164 the duration of, or minimize the severity of an adverse reaction. These steps could
165 include, for example, necessary evaluation prior to use, titration and other kinds of
166 dose adjustment, monitoring during dose adjustment or prolonged use, avoidance of
167 other drugs or substances, or special care during comorbid events (e.g., dehydration,
168 infection)
 - 169 • A discussion of how to treat, or otherwise manage, an adverse reaction that has
170 occurred

171 Although the following issues would typically be discussed elsewhere in labeling, they
172 can also be mentioned in the WARNINGS AND PRECAUTIONS section when such
173 information would help prescribers understand the clinical significance of an adverse
174 reaction:

- 175
- 176 • A discussion of the mechanism of the adverse reaction
 - 177 • The source of information about the adverse reaction (e.g., it may be informative to
178 know whether the information is from clinical trials or postmarketing reports, or
179 whether an adverse reaction was seen only in foreign experience with the drug)

180
181 The information and advice provided in this section should be reasonably qualified,
182 where appropriate, to convey whatever uncertainties may exist about judgments and
183 conclusions made (e.g., concerning causality assessments, estimated adverse reaction
184 rates, and value of proposed monitoring).

185 186 **C. Format**

187 188 *1. Subheadings*

189
190 FDA recommends that each adverse reaction, syndrome, or constellation of reactions
191 (e.g., thrombotic events, hemorrhagic events) included in the WARNINGS AND
192 PRECAUTIONS section have its own subheading. There would ordinarily be no reason

⁴ When the risk for an adverse reaction is highest during early exposure, crude risk (# of adverse reactions/# patients exposed) may be the best estimate. For adverse reactions that occur after prolonged exposure, there should be an adjustment for duration of exposure by use of either overall exposed person time if the risk is constant over time, or by calculation of cumulative incidence for a specified exposure time in a survival analysis.

Contains Nonbinding Recommendations

Draft — Not for Implementation

193 to further subcategorize adverse reactions (e.g., separating observed and expected adverse
194 reactions by placing them under different subheadings).

195
196 2. *Order of Adverse Reactions*

197
198 The order in which adverse reactions are presented should reflect the relative public
199 health significance of the adverse reactions. Factors to consider include the relative
200 seriousness of the adverse reaction, the ability to prevent or mitigate the adverse reaction,
201 the likelihood of occurrence, and the size of the population that is potentially affected. In
202 general, the relative seriousness of the adverse reaction and the ability to prevent or
203 mitigate it weigh more heavily than the likelihood of occurrence or the size of the
204 affected population.

205
206 3. *Emphasis in Text*

207
208 Bolded text, or other emphasis, can be used to highlight particular adverse reactions or
209 parts of the discussion of particular adverse reactions (e.g., steps to be taken to avoid a
210 problem, subpopulations at particular risk). Emphasis should be used sparingly so that its
211 impact is not diminished. When information is to be emphasized, also consider whether
212 that information should be in a boxed warning (see section IV on BOXED WARNING
213 section).

214
215 4. *Cross-Referencing*

216
217 Information discussed in the WARNINGS AND PRECAUTIONS section often is
218 discussed or mentioned in other sections of the labeling (e.g., ADVERSE REACTIONS,
219 DOSAGE AND ADMINISTRATION, DRUG INTERACTIONS). Information
220 appearing in other locations should be appropriately cross-referenced.

221
222
223 **III. CONTRAINDICATIONS SECTION (§ 201.57(c)(5))**

224
225 **A. When to Contraindicate**

226
227 A drug should be contraindicated only in those clinical situations for which the risk from
228 use clearly outweighs any possible therapeutic benefit. Only known hazards, and not
229 theoretical possibilities, must be listed. If there are no known contraindications for a
230 drug, this section must state “None.”

231
232 1. *Observed Adverse Reactions*

233
234 For observed adverse reactions, the following would ordinarily be reason to
235 contraindicate a drug:
236

Contains Nonbinding Recommendations

Draft — Not for Implementation

- 237
- 238
- 239
- The risk of the adverse reaction in the clinical situation to which the contraindication will apply, based on both likelihood and severity of the adverse reaction, outweighs any potential benefit to the patient.

240 **AND**

- 241
- 242
- The causal relationship between exposure to the drug and the adverse reaction is well established.

243

244 2. *Expected Adverse Reactions*

245

246 Adverse reactions that are expected to occur when a drug is used in a specific clinical
247 situation can be the basis for a contraindication.⁵ The following would ordinarily be
248 reason to contraindicate a drug on the basis of an expected adverse reaction.

249

250 The risk of the adverse reaction in the clinical situation to which the contraindication will
251 apply, based on both likelihood and severity of the adverse reaction, outweighs any
252 potential benefit to the patient

253 **AND EITHER**

- 254
- 255
- Based on what is known about the pharmacology, chemistry, or class of the drug, it appears highly likely that the adverse reaction will occur with the drug.

256 **OR**

- 257
- 258
- 259
- Animal data raise substantial concern about the potential for occurrence of the adverse reaction in humans (e.g., animal data demonstrating that a drug has teratogenic effects).

260

261 The labeling should acknowledge that the adverse reaction has not yet been observed, but
262 is expected to occur.

263

264 3. *Likely Clinical Situations*

265

266 A contraindication usually involves one or more of the following clinical situations:

267

- 268
- 269
- 270
- Comorbid condition or coexistent physiological state (e.g., existing hepatic disease, renal disease, congenital long QT syndrome, hypokalemia, pregnancy or childbearing potential, CYP 2D6 poor metabolizer⁶)

271

- 272
- Demographic risk factor (e.g., age, sex, race, genetic vulnerability)

⁵ Expected adverse reactions are distinguishable from “theoretical possibilities” because there are data (e.g., from class, chemistry, animal studies) to support the expected adverse reaction.

⁶ Use of a particular drug in a patient with a slow metabolizer status would be contraindicated only if there were no way to lower the dose to adjust for the compromised metabolic state.

Contains Nonbinding Recommendations

Draft — Not for Implementation

- 273
- 274
- 275
- 276
- 277
- 278
- 279
- 280
- The risks of the drug are such that the drug should never be used in a selected subset of the larger population with a disease⁷
 - Coadministered drug where the combination is dangerous (e.g., MAO inhibitor and sympathomimetic drug, a drug known to prolong the QT interval and a drug known to interfere with the metabolism of that drug)⁸

281

282

283

284

285

Contraindications based on drug interactions with serious outcomes should be described in the CONTRAINDICATIONS section and cross-referenced to more detailed information in the DRUG INTERACTIONS or CLINICAL PHARMACOLOGY sections.

B. Information to Provide

286

287

288

289

For each listed contraindication, provide the following information:

- 290
- 291
- 292
- 293
- 294
- Brief description of the contraindicated situation or scenario, including any pertinent demographic or identifiable predisposing characteristics
 - Description of anticipated consequences of the contraindicated use

C. Format

1. Subheadings

295

296

297

298

299

FDA recommends that each contraindication be identified by its own subheading.

2. Order of Contraindications

300

301

302

303

304

305

306

The order in which contraindications are presented should reflect the relative public health significance of the listed contraindications. Factors to consider include the likelihood of occurrence and the size of the population that is potentially affected.

⁷ The INDICATIONS AND USAGE section must contain information about use of the drug when safety considerations are such that the drug should be reserved for certain patients (e.g., patients with severe disease) or situations (e.g., patients refractory to other drugs) (§ 201.57(c)(2)(i)(B) and (E)). In rare cases, when the risks of the drug clearly outweigh any possible therapeutic benefit and the drug should never be used in a selected patient subset, a contraindication for use of the drug in that subset should also be described in the CONTRAINDICATIONS section.

⁸ There should be consistency across labeling for contraindicated products (i.e., if use of drug A with drug B is contraindicated in the labeling for drug A, the use of drug B with drug A should be contraindicated in the labeling for drug B). For drugs that are regulated in different reviewing divisions, there should be cross-divisional coordination and agreement on contraindicated coadministration of drugs.

Contains Nonbinding Recommendations

Draft — Not for Implementation

307 3. *Text Emphasis*

308
309 Bolded text, or other emphasis, can be used to highlight particular contraindicated
310 situations or parts of the discussions of these situations. Emphasis should be used
311 sparingly so that its impact is not diminished. When information is to be emphasized,
312 also consider whether that information should be in a boxed warning (see BOXED
313 WARNING below).

314

315

316 **IV. BOXED WARNING (§ 201.57(c)(1))**

317

318 **A. When to Use a Boxed Warning**

319

320 A boxed warning is ordinarily used to highlight for prescribers one of the following
321 situations:

322

- 323 • There is an adverse reaction so serious in proportion to the potential benefit from the
324 drug (e.g., a fatal, life-threatening or permanently disabling adverse reaction) that it is
325 essential that it be considered in assessing the risks and benefits of using a drug

326 ***OR***

- 327 • There is a serious adverse reaction that can be prevented or reduced in frequency or
328 severity by appropriate use of the drug (e.g., patient selection, careful monitoring,
329 avoiding certain concomitant therapy, addition of another drug or managing patients
330 in a specific manner, avoiding use in a specific clinical situation)

331 ***OR***

- 332 • FDA approved the drug with restrictions to assure safe use because FDA concluded
333 that the drug can be safely used only if distribution or use is restricted (e.g., under 21
334 CFR part 314, subpart H, § 314.520 “Approval with restrictions to assure safe use”).

335

336 A boxed warning can also be used in other situations to highlight warning information
337 that is especially important to the prescriber. Information included in the WARNINGS
338 AND PRECAUTIONS and CONTRAINDICATIONS sections should therefore be
339 evaluated to determine whether it should also be placed in a boxed warning.

340

341 Boxed warnings are more likely to be based on observed adverse reactions, but there are
342 instances when a boxed warning based on an expected adverse reaction would be
343 appropriate. For example, a contraindication during pregnancy based on evidence in
344 humans that drugs in a pharmacologic class pose a serious risk of developmental toxicity
345 during that time would usually be in a boxed warning for all drugs in that class, even
346 those in which the adverse reaction has not been seen.

347

348 A boxed warning can also be considered for a drug that has important risk/benefit
349 information that is unique among drugs in a drug class (e.g., to note that a drug is the

Contains Nonbinding Recommendations

Draft — Not for Implementation

350 only one in its class to have a particular risk that makes it inappropriate for use as a first
351 line therapy).

352

B. Information to Provide

354

355 A boxed warning provides a brief, concise summary of the information that is critical for
356 a prescriber to be aware of, including any restriction on distribution or use. If there is a
357 more detailed discussion of the concern in either the CONTRAINDICATIONS or
358 WARNINGS AND PRECAUTIONS section, or any other labeling section that contains
359 pertinent information (e.g., DOSAGE AND ADMINISTRATION), a cross-reference to
360 that section must be provided (§ 201.57(c)(1)).

361

C. Format

362

363
364 FDA recommends the information in the boxed warning be presented in a bulleted format
365 (or some alternative format, such as subheadings) that helps to make the information
366 visually accessible.

367

Contains Nonbinding Recommendations

Draft — Not for Implementation

368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395

GLOSSARY

Adverse Reaction (21 CFR 201.57(c)(7)): For purposes of prescription drug labeling and this guidance, an *adverse reaction* is an undesirable effect, reasonably associated with the use of a drug, that may occur as part of the pharmacological action of the drug or may be unpredictable in its occurrence. This definition does not include all adverse events observed during use of a drug, only those for which there is some basis to believe there is a causal relationship between the drug and the occurrence of the adverse event.

Adverse reactions may include signs and symptoms, changes in laboratory parameters, and changes in other measures of critical body function, such as vital signs and electrocardiogram (ECG).

Adverse Event (or adverse experience): For the purposes of this guidance, an *adverse event* refers to any untoward medical event associated with the use of a drug in humans, whether or not considered drug-related.

Serious Adverse Reaction: For purposes of this guidance, the term *serious adverse reaction* refers to any reaction occurring at any dose that results in any of the following outcomes: Death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious adverse drug reactions when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.